English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAbstract This study examines the levels of executive excess compensation (EEC) that stimulate the quality and efficiency of enterprise technology innovation (ETI). Using a behavioral agency perspective, we investigate how companies achieve superior ETI by providing sufficient incentives to motivate…
Tag: Biopharmaceutical
CellFE Announces Addition of Life Science Tools Veteran Mike Rice to Board of Directors
CellFE Inc., a cell engineering platform company with a novel microfluidic technology for non-viral cell therapy manufacturing, announced today that life science tools executive Mike Rice has been appointed to its Board of Directors.
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington’s Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.
Case Western Reserve University biotech startup Rodeo Therapeutics Corp. sold to Amgen Inc.
Rodeo Therapeutics Corp., a drug-development startup founded by two leading researchers from the Case Western Reserve University School of Medicine and a third scientific partner, has been sold to Amgen Inc., a publicly traded international biopharmaceutical company.
Under terms of the agreement, Amgen, based in Thousand Oaks, California, will acquire all outstanding shares of Rodeo for $55 million, plus “future contingent milestone payments potentially worth up to an additional $666 million in cash,” the companies announced today. Total consideration to Rodeo stakeholders could potentially be worth up to $721 million in cash.
Preclinical testing of inhaled monoclonal antibody for COVID-19 shows therapeutic efficacy
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.